Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Absci Corp (ABSI)

Absci Prices $100 Million Stock Offering at $7.41 per Share to Fund ABS-201

Neutral Impact 3 of 5 financing Written later

Absci Corporation agreed to sell 13,495,277 common shares at $7.41 each, with gross proceeds expected to be about $100 million and estimated net proceeds of about $93.5 million. The company plans to use the money to advance ABS-201 for androgenetic alopecia and endometriosis and for working capital and general corporate purposes, and the offering is expected to close on June 25, 2026. The sale adds new shares outstanding, which dilutes existing holders, and Eli Lilly & Company is among the participating investors.

Key points

  • 13,495,277 shares priced at $7.41 per share, with gross proceeds of about $100 million
  • Estimated net proceeds of about $93.5 million after underwriting discounts and offering expenses
  • Proceeds earmarked for ABS-201 in androgenetic alopecia and endometriosis, plus working capital
  • Expected closing on or about June 25, 2026; sold under an S-3 shelf effective August 22, 2025

The filing

CompanyAbsci Corp (ABSI)
Form8-K, current report
Filed with the SECJun 24, 2026, 4:31 PM ET
Accession number0001193125-26-281143

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.